AffyImmune Therapeutics

AffiImmune Therapeutics is a biotechnology startup that aims to enhance the utility and safety of CAR T therapy for cancer patients through its Tune & Track platform. Since its establishment in 2016, the company has been focused on optimizing CAR T cells to effectively target solid tumors while maintaining safety. The company's flagship product, AIC100, is designed to spare healthy cells through unique affinity-tuning, ultimately improving its safety and efficacy. AffyImmune's approach is particularly promising as it addresses the urgent need for effective treatments for refractory thyroid cancer, a disease with a particularly poor prognosis and limited therapeutic options. Furthermore, the targeted antigen of AIC100 is also overexpressed in various other cancers, encompassing stomach cancer, triple-negative breast cancer, and other malignancies. The latest fundraising round, a significant $20.00M Series A investment led by ORI Capital in October 7, 2021, further underscores the investor confidence in AffyImmune's innovative approach to cancer therapy. With a focus on biopharma and biotechnology, the United States-based company has positioned itself as a key player in the pursuit of improved cancer treatments.